GlassScriptPhysician profile
Neil Schrandt
NPI 1003842337
$8,941.98
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,291 · 2020: $1,615 · 2021: $1,948 · 2022: $1,974 · 2023: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $786.06 | 2019-2023 | Vumerity, Tysabri |
| Abbvie INC. | $717.10 | 2019-2023 | Qulipta, Duopa, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $559.37 | 2019-2023 | Austedo, Austedo Xr |
| Jazz Pharmaceuticals INC. | $522.00 | 2019-2023 | Epidiolex, Xywav |
| Novartis Pharmaceuticals Corporation | $479.57 | 2019-2023 | |
| Lilly USA, LLC | $403.56 | 2019-2023 | Amyvid, Reyvow, Emgality |
| Ucb, INC. | $390.93 | 2019-2023 | Briviact |
| Amgen INC. | $366.67 | 2019-2023 | Aimovig |
| Genentech USA, INC. | $348.82 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $237.88 | 2019-2023 | Ultomiris |
| Harmony Biosciences LLC | $236.25 | 2020-2023 | Wakix |
| Biohaven Pharmaceutical Holding Company LTD. | $236.25 | 2022 | |
| Acadia Pharmaceuticals INC | $218.53 | 2019-2023 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $208.72 | 2020-2021 | |
| Emd Serono, INC. | $201.89 | 2019-2023 | Mavenclad |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Schrandt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.